POZEN, ASTRAZENECA TO COLLABORATE ON PAIN KILLERS

AstraZeneca has entered into a deal with Pozen to co-develop fixed-dose combinations of naproxen (Aleve) and esomeprazole (Nexium) for chronic pain.

The development program will be jointly funded, with Pozen responsible for the U.S. development and regulatory filings. Phase III clinical development is expected to start in 2007, with a U.S. submission currently targeted for the end of 2008, the company said.

AstraZeneca will have full responsibility for all international development activities as well as all aspects of manufacturing, marketing, sales and distribution. It will also be responsible for all international regulatory filings. Both parties will contribute scientific, development and regulatory expertise to the collaboration.